- Home
- SGU vs ZURA Comparison
SGU vs ZURA Comparison
Compare SGU & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGU | ZURA |
|---|---|---|
| Founded | 1995 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 455.4M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGU | ZURA |
|---|---|---|
| Price | $12.66 | $3.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 16.2K | ★ 856.3K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.31 | $1.00 |
| 52 Week High | $13.53 | $7.25 |
Technical Indicators
Market Signals| Indicator | SGU | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 37.96 |
| Support Level | $12.34 | $3.25 |
| Resistance Level | $13.02 | $4.12 |
| Average True Range (ATR) | 0.29 | 0.25 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.60 | 39.50 |
Price Performance
Historical ComparisonAbout SGU Star Group L.P.
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.